BANNER HEALTH
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1999-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.bannerhealth.com
Clinical Trials
15
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
- Conditions
- Autosomal Dominant Alzheimers DiseaseEarly Onset Alzheimer DiseaseAlzheimers Disease
- Interventions
- First Posted Date
- 2025-05-30
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Banner Health
- Target Recruit Count
- 240
- Registration Number
- NCT06996730
- Locations
- 🇨🇴
Neurosciences Group of Antioquia, University of Antioquia, Medellin, Antioquia, Colombia
Draw-10: A Weekly Blood Draw Study to Understand the Biological Variability of Plasma pTau-217
- Conditions
- Alzheimer Disease
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Banner Health
- Target Recruit Count
- 100
- Registration Number
- NCT06742944
- Locations
- 🇺🇸
Banner Alzheimer's Institute, Phoenix, Arizona, United States
🇺🇸Banner Alzheimer's Institute Tucson, Tucson, Arizona, United States
Evaluation of Self-Mediated Alternatives for Risk Testing Education and Return of Results
- Conditions
- Alzheimer Disease
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Banner Health
- Target Recruit Count
- 681
- Registration Number
- NCT06459583
- Locations
- 🇺🇸
Accellacare Clinical Research Site 02, Mount Pleasant, South Carolina, United States
🇺🇸Accellacare Clinical Research Site 01, Bristol, Tennessee, United States
Arizona Alzheimer's Disease Research Center (ADRC)
- Conditions
- Alzheimer Disease
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Banner Health
- Target Recruit Count
- 550
- Registration Number
- NCT05405075
- Locations
- 🇺🇸
Banner Alzheimer's Institute, Phoenix, Arizona, United States
🇺🇸Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
APOE in the Predisposition to, Protection From, and Prevention of Alzheimer's Disease
- Conditions
- Alzheimer Disease
- Interventions
- Drug: Amyloid and Tau PET
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Banner Health
- Target Recruit Count
- 300
- Registration Number
- NCT04994847
- Locations
- 🇺🇸
Banner Alzheimer's Institute, Phoenix, Arizona, United States
- Prev
- 1
- 2
- 3
- Next
News
Samsung Acquires Providence Digital Health Spinoff Xealth to Bridge Consumer Wellness and Clinical Care
Samsung Electronics signed an agreement to acquire Xealth, a digital health platform spun out of Providence in 2017 that serves over 500 hospitals and partners with 70+ digital health companies.
Alamar Biosciences Revolutionizes Alzheimer's Detection with Blood-Based Brain-Derived Tau Assays
Alamar Biosciences has expanded its NULISAseq CNS Disease Panel 120 with first-of-its-kind blood-based assays that can specifically detect brain-derived phosphorylated tau proteins, a critical biomarker for Alzheimer's disease.
Top Healthcare Experts Share Insights on Obesity Management, Primary Care Innovation, and Health Equity in 2024 IVBM Coverage
• The Institute for Value-Based Medicine's top coverage in 2024 highlighted critical developments in obesity treatment, including discussions on GLP-1 agonists and multidisciplinary care approaches. • Healthcare leaders emphasized the urgent need for primary care innovation, addressing workforce shortages and implementing AI-driven solutions to enhance care delivery and efficiency. • Experts across multiple institutions stressed the importance of addressing social determinants of health and health inequities in primary care, while advocating for improved metabolic health measurements in obesity care.
Leqembi's Slow Adoption: Challenges and Progress in Alzheimer's Treatment
Leqembi, the first FDA-approved drug shown to slow Alzheimer's progression, has experienced slower-than-expected adoption despite its groundbreaking status in treating the disease.